Because an agonistic antibody against DR4 can act on MM cells without host immune cells and in the presence of osteoprotegerin, the anti-DR4 agonistic antibody with TACE inhibitors may become a novel immunotherapeutic approach against MM. Here, ADAM17 is linked to Miyoshi myopathy.